Conclusion of non-exclusive discount agreement pursuant to § 130a section 8 SGB V by means of an OH model for the active ingredient Aflibercept (ATC code according to WHO: S01LA05; excluding 114.3 mg/ml) as injection solution in a vial
Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Durchstechflasche
Germany
Contract
BuyerAOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen
TypeSupplies
Estimated valuevalue not published
Published12 November 2025
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 45 | 2013–2024 |
| Aliud Pharma GmbH · Laichingen | 41 | 2013–2021 |
| ratiopharm GmbH | 37 | 2016–2024 |
| betapharm Arzneimittel GmbH · Augsburg | 35 | 2013–2021 |
| axicorp Pharma B.V. · EC Den Haag | 30 | 2016–2021 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019282
2020224
2021274
2022178
2023247
2024285
2025539
2026219
Who knows the rhythm prepares instead of reacting.
134
days until the deadline — Thursday 31 December at 21:58
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →